First Wave BioPharma Chairman and CEO Issues Letter to Shareholders
December 13, 2021 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Names Brian Feagan, M.D., to Scientific Advisory Board
December 09, 2021 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma’s CEO and President, James Sapirstein, to Participate in CEO Panel Discussion at 2021 BioFlorida Conference
December 06, 2021 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Biomerica Receives Notice of Allowance from Canadian Patent Office for Patent Covering Irritable Bowel Syndrome (IBS) Food Sensitivity Testing & Treatment
November 04, 2021 06:39 ET
|
Biomerica, Inc.
Studies show that 13-20% of Canadians suffer from IBS at any given time1. The lifetime risk for a Canadian to develop IBS is 30%1. IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc....
Global Inflammatory Bowel Disease Treatment Market worth USD 27800 million by 2027 :Qualiket Research
November 02, 2021 12:19 ET
|
Qualiket Research
Dallas, Texas, United states, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Global Inflammatory Bowel Disease Treatment Market Size, Trends & Growth Opportunity, By Type (Crohn's Disease, Ulcerative...
First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis
October 14, 2021 09:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 14, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Two Additions to Scientific Advisory Board
October 12, 2021 08:30 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 12, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis
September 28, 2021 08:00 ET
|
First Wave BioPharma, Inc.
Preliminary data from prior Phase 1a/2a trial indicated safety of topical formulation of FW-UP and suggested possible favorable efficacy First Proof of Principle for Treatment of Inflammatory...
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
September 21, 2021 12:47 ET
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development...
Inflammatory Bowel Disease Market to Surpass US$ 2,550.3 Million by 2028, Says Coherent Market Insights (CMI)
September 21, 2021 08:40 ET
|
CMI
SEATTLE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global inflammatory bowel disease market is estimated to be valued at US$ 1,821.8 million in 2021 and is...